MCM3AP-AS1: An Indispensable Cancer-Related LncRNA

Yu, Xiao; Zheng, Qingyuan; Zhang, Qiyao; Zhang, Shuijun; He, Yuting; Guo, Wenzhi

doi:10.3389/fcell.2021.752718

Cited by 11 publications

(5 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this network, MCM3AP-AS1 was an important lncRNA,which interacted with several miRNAs. MCM3AP-AS1 has been reported to be dysregulated in a variety of cancers, including breast, prostate, and gastric cancers [24]. This study found that MCM3AP-AS1 is upregulated in colorectal cancer, promoting the proliferation, migration, and invasion of colorectal cancer cells, and inhibiting cell apoptosis.…”

Section: Discussionmentioning

confidence: 60%

M6A methylase related MCM3AP-AS1 promotes the progression of colorectal cancer through the miR-98/IGF2BP1 signaling axis

Ma,

Ren,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To investigate the relationship between N6-methyladenosine (m6A) related Long non-coding RNAs (lncRNAs) and prognosis in colon cancer (COAD) patients, and the effect of M6A methyltransferase RBM15 on downstream genes regulated by MCM3AP-AS1. Methods Download gene expression and clinical data from 552 COAD samples and 44 adjacent cancer samples from TCGA. Use the DESeq2 software package to screen differentially expressed genes (DEG) between COAD and adjacent cancer tissues. Calculate the correlation between m6A related genes and lncRNAs to screen for m6A related lncRNAs. Univariate Cox regression analysis is used to screen for m6A related lncRNAs that are significantly correlated with prognosis. Subsequently, LASSO was used to screen key lncRNAs from prognosis related lncRNAs to construct a risk model. CCK-8, Wound healing assay, Transwell assay, Flow cytometry, FISH assay, RNA pull-down, Double Luciferase activity assay and rescue experiment were used to explore the effect of MCM3AP-AS1 on colorectal cancer and its specific mechanism. Results Bioinformatics analysis constructed a risk model consisting of 12 lncRNAs. The prognosis of patients in the high-risk group is significantly lower than that in the low-risk group. The risk score has been proven to be an independent prognostic factor for COAD. Subsequently, a ceRNA network consisting of 8 m6A related lncRNAs, 23 miRNAs, and 1531 mRNA was established. Cell experiments have confirmed that the M6A methyltransferase RBM15 is significantly upregulated in colorectal cancer cells, which can mediate the regulation of miR-98 expression by MCM3AP-AS1. MCM3AP-AS1 is significantly upregulated in colorectal cancer cells, promoting cell proliferation, migration, invasion, and inhibiting cell apoptosis. The specific molecular mechanism may be to regulate the expression of IGF2BP1 by targeting downstream miR-98. Conclusion MCM3AP-AS1 can target miR-98 to regulate the expression of IGF2BP1, which may be a potential mechanism for the occurrence and development of colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 60%

M6A methylase related MCM3AP-AS1 promotes the progression of colorectal cancer through the miR-98/IGF2BP1 signaling axis

Ma,

Ren,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…MAZ is reported to promote invasiveness of PC cells (40). MCM3AP-AS1 promotes cell migration in PC (41). These factors may cause the upregulation of FOXF2 in PC and FOXF2 perhaps mediates their tumor-promoting effect on PC.…”

Section: Discussionmentioning

confidence: 99%

Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2

Zhong,

Ma,

Sun

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a malignant tumor possessing high mortality. The role of transcription factor Forkhead Box F2 (FOXF2) in PC remains unverified. The current study investigated the roles of FOXF2 in developing PC in vitro and in vivo. A xenograft tumor model was constructed with nude mice injected using FOXF2-overexpressing PC cells or FOXF2-silenced PC cells. High FOXF2 expression significantly enhanced the proliferation ability of PC cells in vitro and pancreatic tumor growth in vivo.The cell cycle analysis indicated that transition of G1-S phase was promoted by FOXF2. The cell cycle-associated proteins cyclin D1, CDK2, phosphorylated (p)-CDK2 and p-RB were upregulated in the FOXF2-overexpressing cells and downregulated in the cells with FOXF2 knockdown. Flow cytometric analysis and Hoechst staining showed that the percentage of apoptotic cells was significantly increased after FOXF2 was silenced. FOXF2 knockdown promoted expression of pro-apoptotic proteins (Bad, Bax and cleaved caspase-3) while suppressing the anti-apoptotic proteins (Bcl-2 and Bcl-xl) at the protein level. FOXF2 improved the migration and invasion of PC cells in vitro. Moreover, luciferase and chromatin immunoprecipitation assays revealed that FOXF2 binds to the MSI2 promoter, promoting its transcriptional expression. FOXF2 knockdown inhibited the MSI2 protein translation while enhancing the translation of NUMB protein, suppressing PC development in vivo. MSI2 silencing reversed the promotive effect mediated by FOXF2 on cell proliferation. These results demonstrated that FOXF2 is essential in PC progression, and the potential mechanism includes regulating MSI2 transcription.

show abstract

“…The MCM3AP gene is associated with autosomal recessive peripheral neuropathy, with or without impaired intellectual development (PNRIID). 3 There is increasing evidence to support the MCM3AP gene with autosomal dominant adenomatous polyposis 9,10 and, more recently, hypokalemic periodic paralysis. 2 PNRIID associated with MCM3AP is often caused biallelic pathogenic Two Cases of Periodic Paralysis www.jcnmd.com…”

Section: Discussionmentioning

confidence: 99%

“…Early research connects it to varying forms of cancer. 9,10 It also has been found in individuals with immunodeficiency, 12 intellectual disability, 13 Alzheimer disease, 14 vascular pathologies, [15][16][17] multiple sclerosis, 17 and Charcot-Marie-Tooth disease. 4,[18][19][20] There is preliminary evidence to suggest pleiotropy in the MCM3AP gene responsible for a periodic paralysis phenotype.…”

Section: Clinical Neuromuscular Diseasementioning

confidence: 99%

Two Cases of Periodic Paralysis Associated With MCM3AP Variants

Oishi,

Pagano,

Sellers

et al. 2023

Journal of Clinical Neuromuscular Disease

View full text Add to dashboard Cite

Objectives: Periodic paralysis is a rare genetic condition characterized by episodes of neuromuscular weakness, often provoked by electrolyte abnormalities, physiologic stress, physical exertion, and diet. In addition to mutations in genes coding for skeletal muscle ion channels, in 2019, Gustavasson et al discovered that the MCM3AP gene could be responsible for periodic paralysis. In this study, we present 2 individuals with clinical episodes of periodic paralysis who have variants in the MCM3AP gene. Methods: Two unrelated probands were independently evaluated with clinical, genetic, and electrodiagnostic testing. Results: Proband 1 is a 46-year-old man who presented with decades of ongoing episodic weakness and fatigue, clinically diagnosed with periodic paralysis and supported by electrodiagnostic studies. Proband 2 is a 34-year-old woman with a history of episodic paralysis since childhood. Genetic testing in both individuals revealed potentially pathogenic variants in the MCM3AP gene. Conclusions: Periodic paralysis is a condition that significantly affects the lives of those diagnosed. The results illustrate that MCM3AP gene variants can been associated with a clinical and electrodiagnostic presentation of periodic paralysis. Additional future research should focus on clarifying any relationship between these genetic variants and the disease, as well as other possible genetic causes.

show abstract

MCM3AP-AS1: An Indispensable Cancer-Related LncRNA

Cited by 11 publications

References 95 publications

M6A methylase related MCM3AP-AS1 promotes the progression of colorectal cancer through the miR-98/IGF2BP1 signaling axis

M6A methylase related MCM3AP-AS1 promotes the progression of colorectal cancer through the miR-98/IGF2BP1 signaling axis

Transcription factor FOXF2 promotes the development and progression of pancreatic cancer by targeting MSI2

Two Cases of Periodic Paralysis Associated With MCM3AP Variants

Contact Info

Product

Resources

About